1809 Portfolio Company Visby Medical Expands Access to At-Home STI Testing Nationwide

At 1809 Capital, we invest in companies building transformative solutions to real-world challenges—and Visby Medical is doing exactly that.

Visby Medical, an 1809 Capital portfolio company, announced new national partnerships with Quest Diagnostics and Labcorp that will bring Visby’s Women’s Sexual Health Test to consumer platforms across the United States. This milestone marks a major step forward in the future of decentralized diagnostics and at-home healthcare.

Visby’s Women’s Sexual Health Test is the first and only FDA-authorized, at-home PCR test for sexually transmitted infections (STIs), delivering lab-quality accuracy without the barriers of traditional in-clinic testing.

The need for accessible, reliable testing is urgent. Nearly 100,000 women in the U.S. lose their fertility each year due to complications from untreated STIs, many of which are “silent” and cause irreversible harm before symptoms ever appear. By enabling early detection from home, Visby is addressing a critical gap in women’s healthcare and helping prevent long-term outcomes through timely diagnosis.

This announcement follows Visby CEO Adam de la Zerda’s appearance on Bloomberg’s “The Pulse,” where he discussed the company’s progress and the broader shift toward decentralized, patient-centric diagnostics. With expanded distribution through Quest and Labcorp, Visby is scaling its impact and making high-quality diagnostics more accessible nationwide.

Watch the full video:

At 1809 Capital, we are proud to support founders and teams who are redefining industries through innovation, precision, and purpose. Visby Medical’s continued momentum reflects our belief that healthcare solutions should be accurate, accessible, and designed around the patient experience.

We congratulate the Visby Medical team on this important milestone and look forward to what’s ahead.